Ryan Douglas graduated with a liberal arts degree and an ill-timed, burgeoning interest in horticulture. While other liberal arts graduates were looking for office space, Douglas was looking at greenhouses.
In 2018, Kostas Ioannou was looking for an opportunity to break into what he saw as a burgeoning market. At the same time, Vitalis Extraction Technology, a manufacturer of CO2 extraction systems, was looking for a representative in Europe. Ioannou now heads up Vitalis’ European Division.
Hannah Deacon has answered these questions before.
When she speaks about her son Alfie, diagnosed as a baby with a vanishingly rare form of epilepsy, and the battle of attrition which would eventually lead to his prescription for medical cannabis, she’s fluent about the particulars of a disease in a way that only two sorts of people are: people who have studied it, and people who have lived with it. She recounts the bruising details of Alfie’s story without reliving them. She doesn’t sound uncaring - just tragically practiced. Hannah Deacon has answered these questions before in dozens of interviews - as the media, the public and the government weighed drug policy against the life of her son.
Looking along the top bar of the VK PREMIUM consultancy website, one of
the tabs stands out. Services on offer are, well, pretty much what you’d
expect: there’s business consulting, training and investment guidance in
energy, agriculture, tourism BRP and technology. There’s a drop-down menu for
the company’s success stories. And then, sitting almost literally front and
centre between the About Us and Contact links, is the ‘Medical Cannabis’ tab - a
star billing for an industry that wasn’t made legal in Greece until early 2018.
Or Engler, CEO of Advanced Canna Technologies, is talking to us about fish.
It’s not, strictly speaking, the topic of our call - sustainable cannabis farming, Israeli agri-tech and the ballooning global market for commercial cannabis will all come later.